Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
9803 | 1054 | 27.4 | 65% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
1105 | 9279 | BEERS CRITERIA//PHARMACOVIGILANCE//MEDICATION RECONCILIATION |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | RISK MANAGEMENT STRATEGY | Address | 29 | 88% | 1% | 14 |
2 | PHARMACOVIGILANCE | Author keyword | 21 | 14% | 14% | 143 |
3 | MEDDRA | Author keyword | 15 | 63% | 1% | 15 |
4 | PROPORTIONAL REPORTING RATIO | Author keyword | 14 | 100% | 1% | 7 |
5 | LESIM | Address | 11 | 69% | 1% | 9 |
6 | UPPSALA MONITORING | Address | 10 | 42% | 2% | 18 |
7 | OBSERVAT MED OUTCOMES PARTNERSHIP | Address | 9 | 83% | 0% | 5 |
8 | EU ADR | Author keyword | 8 | 100% | 0% | 5 |
9 | MINI SENTINEL | Author keyword | 7 | 64% | 1% | 7 |
10 | DISPROPORTIONALITY ANALYSIS | Author keyword | 7 | 53% | 1% | 9 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | PHARMACOVIGILANCE | 21 | 14% | 14% | 143 | Search PHARMACOVIGILANCE | Search PHARMACOVIGILANCE |
2 | MEDDRA | 15 | 63% | 1% | 15 | Search MEDDRA | Search MEDDRA |
3 | PROPORTIONAL REPORTING RATIO | 14 | 100% | 1% | 7 | Search PROPORTIONAL+REPORTING+RATIO | Search PROPORTIONAL+REPORTING+RATIO |
4 | EU ADR | 8 | 100% | 0% | 5 | Search EU+ADR | Search EU+ADR |
5 | MINI SENTINEL | 7 | 64% | 1% | 7 | Search MINI+SENTINEL | Search MINI+SENTINEL |
6 | DISPROPORTIONALITY ANALYSIS | 7 | 53% | 1% | 9 | Search DISPROPORTIONALITY+ANALYSIS | Search DISPROPORTIONALITY+ANALYSIS |
7 | FAERS | 7 | 57% | 1% | 8 | Search FAERS | Search FAERS |
8 | SELF CONTROLLED CASE SERIES | 7 | 41% | 1% | 13 | Search SELF+CONTROLLED+CASE+SERIES | Search SELF+CONTROLLED+CASE+SERIES |
9 | REPORTING ODDS RATIO | 6 | 58% | 1% | 7 | Search REPORTING+ODDS+RATIO | Search REPORTING+ODDS+RATIO |
10 | VACCINE SAFETY | 6 | 13% | 4% | 41 | Search VACCINE+SAFETY | Search VACCINE+SAFETY |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | PHARMACOVIGILANCE | 83 | 38% | 16% | 172 |
2 | MEDICAL OUTCOMES PARTNERSHIP | 29 | 88% | 1% | 14 |
3 | HEALTH CARE DATA | 21 | 90% | 1% | 9 |
4 | DISPROPORTIONALITY | 18 | 34% | 4% | 44 |
5 | SIGNAL GENERATION | 17 | 25% | 6% | 61 |
6 | VACCINE SAFETY | 13 | 41% | 2% | 24 |
7 | REAL TIME SURVEILLANCE | 12 | 75% | 1% | 9 |
8 | LARGE FREQUENCY TABLES | 12 | 63% | 1% | 12 |
9 | MEDICAL DICTIONARY | 11 | 65% | 1% | 11 |
10 | SPONTANEOUS REPORTING SYSTEM | 11 | 45% | 2% | 19 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references |
% act. ref. to same field |
---|---|---|---|---|
Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how? | 2014 | 9 | 22 | 68% |
Quantitative signal detection using spontaneous ADR reporting | 2009 | 116 | 55 | 84% |
Data Mining of the Public Version of the FDA Adverse Event Reporting System | 2013 | 24 | 75 | 56% |
Novel Data-Mining Methodologies for Adverse Drug Event Discovery and Analysis | 2012 | 45 | 43 | 63% |
Improving Postapproval Drug Safety Surveillance: Getting Better Information Sooner | 2015 | 1 | 44 | 25% |
Should we use a case-crossover design? | 2000 | 263 | 40 | 33% |
Pharmacovigilance: methods, recent developments and future perspectives | 2008 | 64 | 25 | 40% |
Postmarketing Safety Surveillance Where does Signal Detection Using Electronic Healthcare Records Fit into the Big Picture? | 2013 | 8 | 61 | 61% |
Decision support methods for the detection of adverse events in post-marketing data | 2009 | 42 | 47 | 72% |
The application of knowledge discovery in databases to post-marketing drug safety: example of the WHO database | 2008 | 19 | 36 | 75% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | RISK MANAGEMENT STRATEGY | 29 | 88% | 1.3% | 14 |
2 | LESIM | 11 | 69% | 0.9% | 9 |
3 | UPPSALA MONITORING | 10 | 42% | 1.7% | 18 |
4 | OBSERVAT MED OUTCOMES PARTNERSHIP | 9 | 83% | 0.5% | 5 |
5 | IMMUNIZAT SAFETY OFF | 4 | 15% | 2.6% | 27 |
6 | INFORMAT COMP MATH | 4 | 75% | 0.3% | 3 |
7 | INTEGRAT EDUC PHARM PHARMACEUT SCI | 4 | 50% | 0.6% | 6 |
8 | WHO ABORATING INT DRUG MONITORING | 4 | 46% | 0.6% | 6 |
9 | POST LICENSING | 3 | 50% | 0.5% | 5 |
10 | OFF BIOSTAT EPIDEMIOL | 3 | 15% | 2.0% | 21 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000216110 | PHARMACOVIGILANCE//ADVERSE DRUG REACTIONS//ADR REPORTING |
2 | 0.0000100783 | JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION//CLINICAL TEXT//MEDICAL LANGUAGE PROCESSING |
3 | 0.0000093959 | ACTIVATION SYNDROME//RISK EVALUATION AND MITIGATION STRATEGIES//REGULATORY ACTIONS |
4 | 0.0000068105 | HOSPITAL CONTROLS//BERKSONS BIAS//CHOICE OF CONTROLS |
5 | 0.0000048844 | BLEEDING ABNORMALITIES//VENOUS THROMBOSIS AND EMBOLISM//ABORATING TRAINING PHARMACOEPIDEMIO |
6 | 0.0000048048 | SUSPECTED ADVERSE DRUG REACTIONS//VET PHARMACOVIGILANCE MED INFORMAT//VETERINARY PHARMACOVIGILANCE |
7 | 0.0000048003 | PROPENSITY SCORE//MATCHED SAMPLING//UNCONFOUNDEDNESS |
8 | 0.0000045257 | ICES UOTTAWA//VACCINATION AGE//TUBERCULIN RESPONSE |
9 | 0.0000042310 | POLYPHARMACOLOGY//NETWORK PHARMACOLOGY//DRUG REPOSITIONING |
10 | 0.0000041281 | DRUG LAG//OFF PHARMACEUT IND//JAPANESE CLINICAL TRIALS |